Prevention of cardiovascular events with antiplatelet treatment: Does time of intake matter for aspirin and ADP receptor blockers?

Dirk Sibbing, Lisa Gross, D. Aradi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Long-term evidence supports a clustering of cardiovascular events in the early morning. Several studies have shown that platelet hyperreactivity to various stimuli is also present at this period of the day. However, the idea of treatment strategies reflecting the circadian variation in platelet reactivity has been largely neglected so far, and this is true despite the huge number of patients being treated with these drugs. Some pharmacodynamic data suggest that early-morning platelet hyper-reactivity may be overcome by shifting aspirin intake to the bedtime. However, there is lack of evidence whether shifting the time of intake or splitting the daily dose of P2Y12-inhibitors with a regular QD dosing (clopidogrel or prasugrel) to the evening would be effective to overcome platelet hyper-reactivity or to suppress the excess of cardiovascular events observed during morning hours. Further research is warranted to clarify whether such a simple and costless effort like dose shifting or splitting may be beneficial to prevent cardiovascular events.

Original languageEnglish
Pages (from-to)3-6
Number of pages4
JournalThrombosis and Haemostasis
Volume115
Issue number1
DOIs
Publication statusPublished - 2016

Fingerprint

Purinergic P2Y Receptor Antagonists
Aspirin
Blood Platelets
clopidogrel
Therapeutics
Cluster Analysis
Research
Pharmaceutical Preparations

Keywords

  • ADP receptors
  • Antiplatelet agents
  • Antiplatelet drugs
  • Clinical trials
  • Platelet pharmacology

ASJC Scopus subject areas

  • Hematology

Cite this

Prevention of cardiovascular events with antiplatelet treatment : Does time of intake matter for aspirin and ADP receptor blockers? / Sibbing, Dirk; Gross, Lisa; Aradi, D.

In: Thrombosis and Haemostasis, Vol. 115, No. 1, 2016, p. 3-6.

Research output: Contribution to journalArticle

@article{0c3ee695fe2c428a81b908e74ba99e22,
title = "Prevention of cardiovascular events with antiplatelet treatment: Does time of intake matter for aspirin and ADP receptor blockers?",
abstract = "Long-term evidence supports a clustering of cardiovascular events in the early morning. Several studies have shown that platelet hyperreactivity to various stimuli is also present at this period of the day. However, the idea of treatment strategies reflecting the circadian variation in platelet reactivity has been largely neglected so far, and this is true despite the huge number of patients being treated with these drugs. Some pharmacodynamic data suggest that early-morning platelet hyper-reactivity may be overcome by shifting aspirin intake to the bedtime. However, there is lack of evidence whether shifting the time of intake or splitting the daily dose of P2Y12-inhibitors with a regular QD dosing (clopidogrel or prasugrel) to the evening would be effective to overcome platelet hyper-reactivity or to suppress the excess of cardiovascular events observed during morning hours. Further research is warranted to clarify whether such a simple and costless effort like dose shifting or splitting may be beneficial to prevent cardiovascular events.",
keywords = "ADP receptors, Antiplatelet agents, Antiplatelet drugs, Clinical trials, Platelet pharmacology",
author = "Dirk Sibbing and Lisa Gross and D. Aradi",
year = "2016",
doi = "10.1160/TH15-05-0430",
language = "English",
volume = "115",
pages = "3--6",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "1",

}

TY - JOUR

T1 - Prevention of cardiovascular events with antiplatelet treatment

T2 - Does time of intake matter for aspirin and ADP receptor blockers?

AU - Sibbing, Dirk

AU - Gross, Lisa

AU - Aradi, D.

PY - 2016

Y1 - 2016

N2 - Long-term evidence supports a clustering of cardiovascular events in the early morning. Several studies have shown that platelet hyperreactivity to various stimuli is also present at this period of the day. However, the idea of treatment strategies reflecting the circadian variation in platelet reactivity has been largely neglected so far, and this is true despite the huge number of patients being treated with these drugs. Some pharmacodynamic data suggest that early-morning platelet hyper-reactivity may be overcome by shifting aspirin intake to the bedtime. However, there is lack of evidence whether shifting the time of intake or splitting the daily dose of P2Y12-inhibitors with a regular QD dosing (clopidogrel or prasugrel) to the evening would be effective to overcome platelet hyper-reactivity or to suppress the excess of cardiovascular events observed during morning hours. Further research is warranted to clarify whether such a simple and costless effort like dose shifting or splitting may be beneficial to prevent cardiovascular events.

AB - Long-term evidence supports a clustering of cardiovascular events in the early morning. Several studies have shown that platelet hyperreactivity to various stimuli is also present at this period of the day. However, the idea of treatment strategies reflecting the circadian variation in platelet reactivity has been largely neglected so far, and this is true despite the huge number of patients being treated with these drugs. Some pharmacodynamic data suggest that early-morning platelet hyper-reactivity may be overcome by shifting aspirin intake to the bedtime. However, there is lack of evidence whether shifting the time of intake or splitting the daily dose of P2Y12-inhibitors with a regular QD dosing (clopidogrel or prasugrel) to the evening would be effective to overcome platelet hyper-reactivity or to suppress the excess of cardiovascular events observed during morning hours. Further research is warranted to clarify whether such a simple and costless effort like dose shifting or splitting may be beneficial to prevent cardiovascular events.

KW - ADP receptors

KW - Antiplatelet agents

KW - Antiplatelet drugs

KW - Clinical trials

KW - Platelet pharmacology

UR - http://www.scopus.com/inward/record.url?scp=84951311209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951311209&partnerID=8YFLogxK

U2 - 10.1160/TH15-05-0430

DO - 10.1160/TH15-05-0430

M3 - Article

C2 - 26334227

AN - SCOPUS:84951311209

VL - 115

SP - 3

EP - 6

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 1

ER -